Biology of secondary leukemia by Andrew M. Brunner, Timothy A. Graubert

Get full text

Management of patients with lower-risk myelodysplastic syndromes by Andrew M. Brunner, Heather A. Leitch, Arjan A. van de Loosdrecht, Nicolas Bonadies

Get full text

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS) by Andrew M. Brunner, Alexander Gavralidis, Najla Al Ali, Anthony Hunter, Rami Komrokji, Amer Zeidan, David A. Sallman

Get full text

Incident adverse events following therapy for acute promyelocytic leukemia by Peter Geon Kim, Kelly Bridgham, Evan C Chen, Mahesh K Vidula, Olga Pozdnyakova, Andrew M Brunner, Amir T. Fathi

Get full text

Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype by Marla M. Jalbut, Aliyah R. Sohani, Paola Dal Cin, Robert P. Hasserjian, Jenna A. Moran, Andrew M. Brunner, Amir T. Fathi

Get full text

<i>TP53</i> Combined Phenotype Score Is Associated with the Clinical Outcome of <i>TP53</i>-Mutated Myelodysplastic Syndromes by Mariko Yabe, Aidana Z. Omarbekova, Meier Hsu, Hannah May, Maria E. Arcila, Ying Liu, Ahmet Dogan, Andrew M. Brunner, Valentina Nardi, Robert P. Hasserjian, Virginia M. Klimek

Get full text

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies by Joan How, Siyang Ren, Jennifer Lombardi‐Story, Meghan Bergeron, Julia Foster, Phillip C. Amrein, Andrew M. Brunner, Amir T. Fathi, Hanno Hock, Anna Khachatryan, Hiroto Kikuchi, Mei Rosa Ng, Jenna Moran, Rupa Narayan, Donna Neuberg, Aura Ramos, Tina Som, Meghan Vartanian, Yi‐Bin Chen, Dan G. Duda, Gabriela S. Hobbs

Get full text